We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Innova Biosciences Introduces New LATEX One-Step Conjugation Kits
Product News

Innova Biosciences Introduces New LATEX One-Step Conjugation Kits

Innova Biosciences Introduces New LATEX One-Step Conjugation Kits
Product News

Innova Biosciences Introduces New LATEX One-Step Conjugation Kits


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Innova Biosciences Introduces New LATEX One-Step Conjugation Kits"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Innova Biosciences has announced the launch of new red, black and blue 400nm LATEX conjugation kits. Innova Biosciences’ LATEX conjugation kits are one-step kits for the covalent conjugation of antibodies and proteins to specially treated latex beads, for use in the diagnostics field and across other applications.

The new conjugation kits are easy to use, and offer quick, effective conjugation of antibodies, proteins and peptides to latex beads, offering the potential to simplify and improve assay development whilst reducing development timelines.

Additionally, as a variety of colours are available, the range enables multiplexing and therefore maximum flexibility in assay design. The kits are suitable for use in development of diagnostics, in lateral flow assays, and across a range of other applications, and are fully compatible with human serum.

Conjugation to latex particles using conventional methodology is complex and time-consuming, and typically requires extensive optimisation and relatively large quantities of antibody, with aggregation often a major problem associated with covalent conjugations, and extensive pH optimisation required for passive conjugation techniques.

Dr Nick Gee, CEO of Innova Biosciences, commented: “Innova developed the new LATEX conjugation kits in response to customer feedback on the need for a quick and easy alternative to conventional methods. The new kits build upon Innova’s quickly expanding particle range, offering increased flexibility to those working within the diagnostics field.”

Advertisement